ALGS
Aligos Therapeutics Inc
NASDAQ: ALGS · HEALTHCARE · BIOTECHNOLOGY
$5.99
+0.34% today
Updated 2026-04-30
Market cap
$36.94M
P/E ratio
—
P/S ratio
16.90x
EPS (TTM)
$-2.45
Dividend yield
—
52W range
$4 – $14
Volume
0.2M
Aligos Therapeutics Inc (ALGS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-6.05M | $-46.77M | $-74.26M | $-115.66M | $-79.39M | $-79.00M | $-80.74M | $-82.50M |
| Capital expenditures | $2.52M | $2.79M | $2.06M | $892000.00 | $943000.00 | $19000.00 | $130000.00 | $437000.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $179000.00 | $752000.00 | $2.98M | $13.46M | $14.69M | $12.65M | $8.45M | $5.04M |
| Free cash flow | $-8.56M | $-49.55M | $-76.33M | $-116.55M | $-80.33M | $-79.02M | $-80.87M | $-82.94M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $150.84M | $-33.96M | $-105.52M | — | — | — |